Pre-operative Mocetinostat (MGCD0103) and Durvalumab (MEDI4736) (PRIMED) for Squamous Cell Carcinoma of the Oral Cavity
Status:
Withdrawn
Trial end date:
2017-12-21
Target enrollment:
Participant gender:
Summary
This is a Phase 1 Window of Opportunity study to evaluate the pharmacodynamic and immune
effects of pre-operative therapy with Mocetinostat and Durvalumab on patients with squamous
cell carcinoma of the oral cavity.